IDO Don’ts: After Immunotherapy Failure, Experts Say Slow Down – Xconomy
Xconomy |
IDO Don’ts: After Immunotherapy Failure, Experts Say Slow Down
Xconomy They were a top choice to combine with the powerful but limited immunotherapies that have emerged this decade to fight many types of cancer. IDO inhibitors would broaden immunotherapy’s reach, the thinking went. “Everything is starting to come together … |
|
Janssen begins phase 1b/2 clinical trial to assess multiple myeloma …
Pharmaceutical Business Review Janssen has commenced a phase 1b/2 clinical development program to assess JNJ-68284528 (developed based on Legend’s LCAR-B38M), a chimeric … |
STAT |
Stem cell bank opens with backing from leading scientists – Stat
STAT The company’s sales pitch has raised eyebrows among outside experts — especially considering the pedigree of its advisers and their history of speaking out … Some blood stem cells are better than othersScience Daily Global Stem Cell Banking Market Expected to Reach $6956 Million by 2023, Says Allied Market ResearchPR Newswire (press release) Study shows blood stem cells compensate for immune cell deficienciesNews-Medical.net PR Newswire UK (press release) all 235 news articles » |
News-Medical.net |
Mesoblast and Cartherics form partnership to develop ‘off-the-shelf’ CAR–T therapies for solid cancers
News-Medical.net Relapsed Ovarian and Gastric Cancers Initial Targets for Allogeneic CAR–T Cells. Mesoblast Limited today announced that it has entered into a partnership with Cartherics Pty Ltd to develop allogeneic ‘off-the-shelf’ CAR–T cells armed with multiple … |
News-Medical.net |
Mesoblast and Cartherics form partnership to develop ‘off-the-shelf’ CAR–T therapies for solid cancers
News-Medical.net Relapsed Ovarian and Gastric Cancers Initial Targets for Allogeneic CAR–T Cells. Mesoblast Limited today announced that it has entered into a partnership with Cartherics Pty Ltd to develop allogeneic ‘off-the-shelf’ CAR–T cells armed with multiple … |